Drugs / MET409
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04702490 | Dec 2020 → Apr 2022 | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Metacrine, Inc. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MET409 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04702490 ↗ |